%0 Journal Article
%T Familial Hypercholesterolemia: From Clinical Suspicion to Novel Treatments.
%A Mirzai S
%A Chevli PA
%A Rikhi R
%A Shapiro MD
%J Rev Cardiovasc Med
%V 24
%N 11
%D 2023 Nov
%M 39076456
%F 4.43
%R 10.31083/j.rcm2411311
%X Familial hypercholesterolemia (FH) is the most common monogenic disorder in humans. It affects millions of people globally, increasing the risk of developing cardiovascular disease (CVD) at a younger age due to elevated levels of low-density lipoprotein cholesterol (LDL-C) from birth. While effective traditional and novel treatments are available, the most significant challenge with FH is the lack of timely diagnosis. As a result, many patients remain undertreated leading to an increased risk of CVD. To mitigate risk, initiating early and aggressive LDL-C-lowering therapies is recommended. Moreover, given its autosomal dominant inheritance patterns, it is also recommended to perform cascade lipid and/or genetic testing of all first-degree relatives. This review highlights the importance of early FH diagnosis and available treatment options. Greater awareness and improved screening efforts can help diagnose and treat more individuals, ultimately reducing the CVD risk associated with FH.